Lightship Partners with Castor to Scale Virtual Trials
Lightship and Castor have announced a strategic partnership to run direct-to-patient (hybrid) clinical trials at scale.
For decades, clinical trials have experienced low rates of participation relative to the distribution of a condition, which can impact the ability to access diverse patient populations and construct a representative sample. One of the main reasons for this is the high burden of participation that patients often experience. Lightship’s delivery model combined with an in-house care team will provide the patient experience in clinical trials partnering with Castor’s globally compliant Decentralized Clinical Trial and Clinical Data Management platform.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
